Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries flag tag at the N-terminus and polyhistidine tag at the C-terminus.
The protein has a calculated MW of 58.6 kDa. The protein migrates as 43-45 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE).
>90% as determined by SDS-PAGE.
This product is not suitable for cell based experiments due to cytotoxicity of detergent.
Detergent buffer is INDISPENSABLE to keep membrane protein soluble and active, under no circumastance should you remove detergent.
Detergent buffer is sold separately and not included in protein, and please contact us if you need the buffer.
If glycerol is not compatible to your application, remove glycerol just before immediate experiment, and NEVER store glycerol-free protein solution.
Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, Buffer B, pH7.5 with glycerol as protectant.
Contact us for customized product form or formulation.
This product is supplied and shipped with dry ice, please inquire the shipping cost.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CNR1 Protein, Flag,His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Immobilized Human CNR1 Protein, Flag,His Tag (Cat. No. CN1-H55D3) at 5 μg/mL (100 μL/well) on Nickel Coated plates (Cat. No. SP-19) can bind Anti-CNR1 Antibody, Human IgG4 with a linear range of 0.6-10 ng/mL (QC tested).
Anti-CNR1 Antibody, Human IgG4 captured on Protein A Chip can bind Human CNR1 Protein, Flag,His Tag (Cat. No. CN1-H55D3) with an affinity constant of 42.8 nM as determined in a SPR assay (in presence of LMNG and CHS) (Biacore 8K) (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Cannabidiol/Dronabinol | THC-5; delta-9-THC/CBD; MPL-001; MPL-005; GW-1000; KL16-012; BOL-DP-o-04; GW-1000-02; PPP-001; MGC-ODT | Approved | Gw Pharmaceuticals | Sativex, Qixleef | Canada | Muscle Spasticity; Neuralgia; Cancer Pain; Chronic Pain; Multiple Sclerosis | null | 2005-04-01 | Dementia; Panic Disorder; Phobia, Social; Neuralgia, Postherpetic; Huntington Disease; Reflex Sympathetic Dystrophy; Tourette Syndrome; Muscle Spasticity; Malnutrition; Sciatica; Acute Pain; Neuromyelitis Optica; Arthritis, Psoriatic; Neuralgia; Urinary Bladder, Overactive; Back Pain; Osteoarthritis, Knee; Hepatic Insufficiency; Stress Disorders, Post-Traumatic; Healthy Aging; Hidradenitis Suppurativa; Agoraphobia; Drug Resistant Epilepsy; Renal Insufficiency, Chronic; Social Behavior; Corticobasal degeneration; Cerebral Palsy; Low Back Pain; Agitation; Sleep Initiation and Maintenance Disorders; Peripheral Nervous System Diseases; Genital Diseases, Male; Pain; Chronic Pain; Depression; Depressive Disorder, Major; Marijuana Abuse; Marijuana Use; Spasm; Squamous Cell Carcinoma of Head and Neck; Cancer Pain; Renal Insufficiency; Migraine Disorders; Spinal Cord Injuries; Neoplasms; Arthritis, Rheumatoid; Neck Pain; Diabetic Neuropathies; Sleep Wake Disorders; Opioid-Related Disorders; Essential Tremor; Anorexia; | Details |
Cannabidiol | AVCN-583601; GLA-015; BTX-1503; BTX-1801; BTX-1702; LYT-310; RAD011; PBX-1308; RAD-011; BRCX-014; RLS-103; GWP-42003; GWP-42003-P; BOL-DP-o-05; GW-42003; BTX-1204; ZYN-002; PTL-101; CHI-902; APH-1501 | Approved | Gw Pharmaceuticals Plc | Epidiolex, Epidyolex, Zygel, Cannepil | United States | Epilepsies, Myoclonic; Lennox Gastaut Syndrome | null | 2018-06-25 | Tobacco Smoking; Migraine Disorders; Peripheral Nervous System Diseases; Acne Vulgaris; HIV Infections; Ovarian Neoplasms; Sleep Initiation and Maintenance Disorders; Facial Pain; Substance-Related Disorders; Marijuana Smoking; Tobacco Use Cessation; Seizures; Tuberous Sclerosis; Pain; Schizophrenia; Chronic Pain; Marijuana Use; Anxiety; Rett Syndrome; Appetitive Behavior; Autism Spectrum Disorder; Marijuana Abuse; Brain Injuries, Traumatic; Depression; Alcoholic Intoxication; Inflammatory Bowel Diseases; Fatty Liver; Child Behavior Disorders; Diabetes Mellitus, Type 2; Spinal Cord Injuries; Muscle injury; Neoplasms; Psychotic Disorders; Opioid-Related Disorders; Diabetic Neuropathies; Coronavirus Disease 2019 (COVID-19); Musculoskeletal Pain; Anxiety Disorders; Sleep Wake Disorders; Graft vs Host Disease; Blepharospasm; Dyspepsia; Arthritis, Rheumatoid; Hyperalgesia; Chronic Urticaria; Hoarding Disorder; Bipolar Disorder; Pancreatic Neoplasms; Brain Diseases; Dysmenorrhea; Sturge-Weber Syndrome; Memory; Mult | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Dronabinol(AXIM Biotechnologies) | Phase 3 Clinical | Axim Biotechnologies Inc | Neoplasms; Nutrition Disorders; Child Nutrition Disorders; Vomiting; Nausea; Cachexia; Sarcopenia; Anorexia Nervosa | Details | |
Adezunap | AP-707 | Phase 3 Clinical | CannaXan GmbH | Stroke; Peripheral Nerve Injuries; Diabetes Mellitus; Low Back Pain; Accidental Injuries; Diabetic peripheral neuropathy; Neuralgia; Back Pain; Phantom Limb; Multiple Sclerosis; Peripheral Nervous System Diseases; Brachial Plexus Neuropathies; Somatoform Disorders; Diabetic Neuropathies; Pain, Postoperative; Paraplegia; Chronic Pain; Brain Injuries, Traumatic; Pain | Details |
Dronabinol(Vertanical) | VER-01 | Phase 3 Clinical | Vertanical GmbH | Low Back Pain | Details |
cannabidiol (Cardiol Therapeutics) | Phase 3 Clinical | Cardiol Therapeutics Inc | Coronavirus Disease 2019 (COVID-19); Pericarditis; Cardiovascular Diseases; Myocarditis | Details | |
V-24343 | V-24343; ANEB-001 | Phase 2 Clinical | Vernalis Plc | Poisoning; Obesity | Details |
11C-MePPEP | 11C-MePPEP | Phase 2 Clinical | Eli Lilly And Company | Substance-Related Disorders; Obesity | Details |
AX-1602 | AX-1602 | Phase 2 Clinical | Axim Biotechnologies Inc | Psoriasis; Dermatitis, Atopic; Vitiligo | Details |
Nimacimab | RYI-018; RYI-028; JNJ-2463 | Phase 2 Clinical | Bird Rock Bio Inc | Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity; Renal Insufficiency, Chronic; Diabetic Gastroparesis | Details |
ART-2713 | NEO-1940; ART-2713; ART27.13; AZD-1940 | Phase 2 Clinical | Astrazeneca Plc, Neomed Inc, Pfizer Inc | Weight Loss; Pain; Anorexia; Cachexia; Low Back Pain | Details |
AEF-0217 | AEF-0217 | Phase 2 Clinical | Aelis Farma | Down Syndrome | Details |
Monlunabant | S-MRI-1891; (-)-MRI-1891; NN9440–INV-202; INV-202; MRI-1891 | Phase 2 Clinical | Inversago Pharma Inc | Metabolic Syndrome; Metabolic Diseases; Diabetic Nephropathies; Obesity | Details |
C20T5 | C20T5 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
C12T12 | C12T12 | Phase 2 Clinical | Murdoch Childrens Research Institute | Details | |
Tetrahydrocannabinol valine hemisuccinate (Skye Bioscience) | NB-1111; Sb-100 OE; SBI-100 OE; THC-VHS-NEC; THCVHS; SBI-100; THCVHS-N; UM-5050; THCVHS-NE | Phase 2 Clinical | University Of Mississippi | Glaucoma, Open-Angle; Glaucoma; Ocular Hypertension | Details |
IGC-AD1 | IGC-AD1 | Phase 2 Clinical | University Of South Florida | Dementia; Psychomotor Agitation; Alzheimer Disease | Details |
AEF-0117 | AEF-0117 | Phase 2 Clinical | National Institute On Drug Abuse, Aelis Farma | Marijuana Abuse | Details |
[11C]OMAR | [11C]JHU-75528 | Phase 1 Clinical | Johns Hopkins University School Of Medicine | Schizophrenia; Marijuana Abuse | Details |
ZYN-001 | ZYN-001 | Phase 1 Clinical | Zynerba Pharmaceuticals | Neuralgia; Fibromyalgia | Details |
Tetrahydrocannabivarin | GWP-42004; THCV; O-4394; DELTA9-THCV; GW-42004 | Phase 1 Clinical | Gw Pharmaceuticals Plc | Diabetes Mellitus, Type 2; Metabolic Syndrome; Obesity, Morbid; Hypercholesterolemia; Hyperglycemia; Dyslipidemias | Details |
Cannabidiol/hydroxychloroquine | IHL-675A; IHL-675 | Phase 1 Clinical | Incannex Healthcare Ltd | Arthritis, Rheumatoid; Respiratory Distress Syndrome, Adult | Details |
Zevaquenabant | MRI-1867; (S)-MRI-1867; INV-101 | Phase 1 Clinical | National Institutes Of Health | Scleroderma, Systemic | Details |
Atorvastatin Calcium Hydrate/Cannabidiol | Phase 1 Clinical | Indication Bioscience LLC | Coronary Disease; Dyslipidemias | Details | |
TPT0301 | TPT-0301; TPT0301 | Phase 1 Clinical | Tetra Pharm Technologies ApS | Chronic Pain | Details |
INV-347 | NN9441; NN-9441; INV-347 | Phase 1 Clinical | Inversago Pharma Inc | Obesity | Details |
IPI 201(Isosceles Pharmaceuticals Inc ) | IPI-201 | Phase 1 Clinical | Pain, Postoperative | Details | |
GFB-024 | Phase 1 Clinical | Takeda Pharma | Kidney Diseases; Endocrine System Diseases; Diabetes Complications; Diabetic Nephropathies; Diabetes Mellitus | Details | |
DBPR-211 | Phase 1 Clinical | National Health Research Institutes | Diabetes Mellitus, Type 2 | Details | |
MP-10X | MP-10X | Clinical | Medipure Holdings | Pain | Details |
MP-20X | MP-20X | Clinical | Medipure Holdings | Mood Disorders; Anxiety Disorders | Details |
Cannabidiol (Receptor Life Sciences) | Clinical | Receptor Life Sciences Inc | Autism Spectrum Disorder | Details | |
Cannabidiol/Palmitoylethanolamide | THX-210; SCI–210 | Clinical | Therapix Biosciences Ltd | Autism Spectrum Disorder; Diabetic Neuropathies | Details |
This web search service is supported by Google Inc.